Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants

Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants

Nov 13, 2017
Source URL: https://qa1.novartis.us/news/media-releases/novartis-canakinumab-acz885-reduced-cardiovascular-risk-25-subgroup-cantos-phase-iii-trial-participants-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-canakinumab-acz885-reduced-cardiovascular-risk-25-subgroup-cantos-phase-iii-trial-participants-0